SEARCH

SEARCH BY CITATION

Keywords:

  • hepatic impairment;
  • influenza;
  • oseltamivir;
  • oseltamivir carboxylate;
  • pharmacokinetics

Aims

To compare the pharmacokinetics of oseltamivir and oseltamivir carboxylate in hepatically impaired patients and healthy subjects.

Methods

Hepatically impaired patients (n = 11) and healthy subjects (n = 11) were individually paired on the basis of gender, age (±10 years) and body weight (±20%) and administered a single dose of oseltamivir (75 mg).

Results

Oseltamivir and oseltamivir carboxylate Cmax were ≤6% and ≤19% lower, and their AUC(0,∞) 33% higher and ≤19% lower, respectively, in hepatically impaired patients compared with healthy subjects. These changes are within the safety limits for the drug.

Conclusions

The metabolism of oseltamivir is not compromised minimally in hepatically impaired patients. No dose adjustment is required in these patients when receiving oseltamivir.